Hospital-onset Gram-negative Surveillance Program annual report, 2011

Authors

  • John D Turnidge Microbiology and Infectious Diseases, SA Pathology, Women’s and Children’s Hospital, North Adelaide, South Australia; Departments of Pathology, Paediatrics and Molecular Biosciences, University of Adelaide, South Australia
  • Thomas Gottlieb Department of Microbiology and Infectious Diseases, Concord, Concord, New South Wales
  • David H Mitchell Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, New South Wales
  • Geoffrey W Coombs Australian Collaborating Centre for Enterococcus and Staphylococcus Species (ACCESS) Typing and Research, School of Biomedical Sciences, Curtin University, Perth, Western Australia; Department of Microbiology and Infectious Diseases, PathWest Laboratory Medicine, WA, Royal Perth Hospital, Perth, Western Australia
  • Julie C Pearson Department of Microbiology and Infectious Diseases, PathWest Laboratory Medicine, WA, Royal Perth Hospital, Perth, Western Australia
  • Jan M Bell Microbiology and Infectious Diseases, SA Pathology, Women’s and Children’s Hospital, North Adelaide, South Australia
  • Australian Group on Antimicrobial Resistance

DOI:

https://doi.org/10.33321/cdi.2014.38.10

Keywords:

antibiotic resistance, hospital onset, gram-negative, Escherichia coli, Enterobacter, Klebsiella

Abstract

The Australian Group on Antimicrobial Resistance performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric Gram-negative pathogens. The 2011 survey focussed on hospital-onset infections, examining isolates from all specimens presumed to be causing disease. In 2011, 1,827 Escherichia coli, 537 Klebsiella species and 269 Enterobacter species were tested using a commercial automated method (Vitek 2, BioMérieux) and results were analysed using Clinical and Laboratory Standards Institute breakpoints from January 2012. Of the key resistances, non-susceptibilty to the third-generation cephalosporin, ceftriaxone, was found in 9.6% of E. coli and 9.5%–12.1% ofKlebsiella spp. Non-susceptibility rates to ciprofloxacin were 10.6% for E. coli, 0.0%–8.3% for Klebsiella spp. and 0.0%–5.0% in Enterobacter spp. Resistance rates to gentamicin were 8.6%, 2.9%–10.9%, and 0.0%–15.6% for the same 3 groups respectively. Eight strains, 5 Klebsiella spp. and 3 Enterobacter spp. were shown to harbour a carbapenemase (IMP-4). Commun Dis Intell 2014;38 (1):E49–E53.

Downloads

Download data is not yet available.

References

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-Second Informational Supplement M100–S22. Villanova, PA, USA 2012.

Hanson ND, Thomson KS, Moland ES, Sanders CC, Berthold G, Penn RG. Molecular characterization of a multiply resistant Klebsiella pneumoniae encoding ESBLs and a plasmid-mediated AmpC. J Antimicrob Chemother 1999;44(3):377–380.

Chia JH, Chu C, Su LH, Chiu CH, Kuo AJ, Sun CF, et al. Development of a multiplex PCR and SHV melting-curve mutation detection system for detection of some SHV and CTX-M b-lactamases of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae in Taiwan. J Clin Microbiol 2005;43(9):4486–4491.

Birkett CI, Ludlam HA, Woodford N, Brown DFJ, Brown NM, Roberts MTM, et al. Real-time TaqMan PCR for rapid detection and typing of genes encoding CTX-M extended-spectrum ß-lactamases. J Med Microbiol 2007;56(Pt 1):52–55.

Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002;40(6):2153–2162.

Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004;48(1):15–22.

Mendes RE, Kiyota KA, Monteiro J, Castanheira M, Andrade SS, Gales AC, et al. Rapid detection and identification of metallo-ß-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. J Clin Microbiol 2007;45(2):544–547.

Turnidge J, Gottlieb T, Mitchell D, Pearson J for the Australian Group for Antimicrobial Resistance. Gram-negative Survey, 2008 Antimicrobial Susceptibility Report. 2011. Adelaide: Australian Group for Antimicrobial Resistance. Available from: http://www.agargroup.org/files/AGAR%20GNB08%20Report%20FINAL.pdf

Sheng WH, Badal RE, Hsueh PR; SMART Program. Distribution of extended-spectrum ß-lactamases, AmpC ß-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia–Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2013;57(7):2981–2988.

Sidjabat H, Nimmo GR, Walsh TR, Binotto E, Htin A, Hayashi Y, Li J, Nation RL, George N, Paterson DL. Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi metallo-ß-lactamase. Clin Infect Dis 2011;52(4):481–484.

Coatsworth NR, Huntington PG, Hardiman RP, Hudson BJ, Fernandes CJ. A case of carbapenemase-producing Klebsiella pneumoniae in Australia. Pathology 2012;44(1):42–44.

Downloads

Published

01/03/14

How to Cite

Turnidge, John D, Thomas Gottlieb, David H Mitchell, Geoffrey W Coombs, Julie C Pearson, Jan M Bell, and Australian Group on Antimicrobial Resistance. 2014. “ Hospital-Onset Gram-Negative Surveillance Program Annual Report, 2011”. Communicable Diseases Intelligence 38 (March):49-53. https://doi.org/10.33321/cdi.2014.38.10.

Issue

Vol. 38 (2014)

Section

Annual report

Categories

License

Copyright (c) 2014 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 > >>